Your browser is no longer supported. Please, upgrade your browser.
RTRX Retrophin, Inc. daily Stock Chart
RTRX [NASD]
Retrophin, Inc.
Index- P/E- EPS (ttm)-2.89 Insider Own1.30% Shs Outstand43.12M Perf Week-3.56%
Market Cap1.01B Forward P/E- EPS next Y-2.26 Insider Trans-7.06% Shs Float36.54M Perf Month32.23%
Income-123.60M PEG- EPS next Q-0.52 Inst Own88.70% Short Float11.14% Perf Quarter21.16%
Sales183.50M P/S5.51 EPS this Y-36.20% Inst Trans2.69% Short Ratio7.94 Perf Half Y33.16%
Book/sh5.23 P/B3.83 EPS next Y-35.30% ROA-17.20% Target Price28.63 Perf Year-4.62%
Cash/sh7.07 P/C2.83 EPS next 5Y20.00% ROE-43.20% 52W Range8.98 - 21.91 Perf YTD41.13%
Dividend- P/FCF- EPS past 5Y4.80% ROI-32.20% 52W High-8.53% Beta0.86
Dividend %- Quick Ratio5.90 Sales past 5Y44.10% Gross Margin97.00% 52W Low123.16% ATR0.93
Employees221 Current Ratio6.00 Sales Q/Q20.70% Oper. Margin-62.20% RSI (14)63.72 Volatility3.93% 5.28%
OptionableYes Debt/Eq0.00 EPS Q/Q57.90% Profit Margin-57.00% Rel Volume0.81 Prev Close20.14
ShortableYes LT Debt/Eq0.92 EarningsMay 11 AMC Payout- Avg Volume512.18K Price20.04
Recom1.60 SMA2011.11% SMA5019.62% SMA20036.47% Volume413,006 Change-0.50%
Jun-17-20Initiated BTIG Research Buy $25
Feb-25-20Downgrade Barclays Overweight → Equal Weight $19
Apr-22-19Initiated Barclays Overweight
Nov-19-18Initiated Nomura Buy $57
Aug-17-18Initiated Canaccord Genuity Buy $36
Nov-02-15Initiated JMP Securities Mkt Outperform $30
Jun-04-15Reiterated Deutsche Bank Buy $52 → $55
May-15-15Initiated Avondale Mkt Outperform
Apr-28-15Initiated Deutsche Bank Buy $50
Jun-26-20 08:21AM  
Jun-25-20 08:42AM  
Jun-19-20 08:00AM  
Jun-17-20 01:55PM  
Jun-08-20 10:02PM  
04:01PM  
May-27-20 04:30PM  
May-12-20 01:01PM  
May-11-20 06:05PM  
04:01PM  
Apr-28-20 12:33PM  
Apr-27-20 04:30PM  
Apr-11-20 10:25AM  
Apr-09-20 04:30PM  
Mar-18-20 10:01AM  
Mar-09-20 08:00AM  
Mar-08-20 09:01PM  
Feb-28-20 08:00AM  
Feb-24-20 04:01PM  
Feb-19-20 04:30PM  
Feb-13-20 05:00PM  
Feb-11-20 12:45PM  
Feb-10-20 04:30PM  
Jan-13-20 06:59AM  
Dec-18-19 07:59AM  
Dec-12-19 10:54AM  
Dec-10-19 03:57PM  
Nov-15-19 02:13PM  
Nov-14-19 04:30PM  
Nov-08-19 10:04AM  
Nov-07-19 10:21AM  
09:17AM  
Oct-30-19 07:05PM  
04:01PM  
Oct-28-19 06:04PM  
Oct-23-19 10:34AM  
Oct-16-19 04:30PM  
Oct-11-19 04:05PM  
Oct-01-19 04:30PM  
11:31AM  
Sep-26-19 04:30PM  
Aug-28-19 10:34AM  
Aug-23-19 07:38AM  
Aug-22-19 04:33PM  
04:15PM  
02:00PM  
10:42AM  
07:59AM  
07:18AM  
06:32AM  
06:13AM  
06:00AM  
Aug-19-19 09:55AM  
Aug-14-19 04:25AM  
Aug-07-19 08:25AM  
Aug-06-19 06:45PM  
Jul-31-19 04:30PM  
09:59AM  
Jul-30-19 10:38AM  
Jul-23-19 04:30PM  
Jul-18-19 10:33AM  
Jun-29-19 08:25AM  
Jun-28-19 06:15AM  
Jun-25-19 02:30PM  
02:28PM  
Jun-21-19 09:06AM  
Jun-20-19 05:13PM  
04:33PM  
Jun-18-19 04:30PM  
Jun-03-19 12:33PM  
May-31-19 05:41PM  
02:55PM  
May-30-19 04:30PM  
May-13-19 06:30PM  
08:00AM  
May-08-19 03:24PM  
May-07-19 06:35PM  
05:26PM  
04:01PM  
02:30PM  
10:55AM  
Apr-30-19 10:32AM  
09:30AM  
Apr-26-19 12:19PM  
Apr-23-19 04:30PM  
Mar-24-19 08:13AM  
Mar-14-19 11:20AM  
Mar-07-19 12:53PM  
Mar-06-19 08:15AM  
Mar-05-19 04:30PM  
Feb-28-19 08:00AM  
Feb-26-19 10:01PM  
04:01PM  
02:30PM  
Feb-14-19 04:30PM  
Feb-12-19 04:30PM  
Feb-08-19 08:03AM  
Feb-04-19 07:35AM  
Jan-17-19 06:55AM  
Jan-07-19 07:00AM  
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASELAGE STEVEDirectorJun 25Sale20.0010,000200,000238,732Jun 29 09:02 PM
ASELAGE STEVEDirectorMay 14Sale15.093,06246,206245,732May 14 08:59 PM
ASELAGE STEVEDirectorMay 13Sale16.414,06366,674248,794May 14 08:59 PM
ASELAGE STEVEDirectorMay 12Sale17.161,00017,160252,857May 14 08:59 PM
Rosenberg Noah L.Chief Medical OfficerMay 12Sale16.985278,95126,728May 13 09:00 PM
Clague LauraChief Financial OfficerMay 12Sale17.111,77730,40119,473May 13 09:00 PM
ROTE WILLIAM E.Senior Vice President, R&DMay 12Sale17.091,33922,88523,494May 13 09:00 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryMay 12Sale17.071,05217,96025,431May 13 09:00 PM
Clague LauraChief Financial OfficerMay 11Sale14.951,25018,68821,250May 13 09:00 PM
ROTE WILLIAM E.Senior Vice President, R&DMay 11Sale14.9581312,15424,833May 13 09:00 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryMay 11Sale14.955257,84926,483May 13 09:00 PM
ASELAGE STEVEDirectorMay 05Sale15.882,50039,700253,857May 06 04:09 PM
ROTE WILLIAM E.Senior Vice President, R&DMar 10Sale14.873,25048,32825,646Mar 12 07:45 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryMar 10Sale15.023,50052,57027,008Mar 12 07:44 PM
Clague LauraChief Financial OfficerMar 10Sale15.024,00060,08022,500Mar 12 07:43 PM
Rosenberg Noah L.Chief Medical OfficerMar 05Sale15.361,79027,48727,255Mar 09 09:05 PM
ASELAGE STEVEDirectorMar 05Sale15.364,35966,939256,357Mar 09 09:03 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 18Sale16.551,25020,68825,646Feb 19 04:05 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 14Sale16.721,25020,90026,896Feb 19 04:05 PM
ASELAGE STEVEDirectorFeb 05Sale16.622,50041,550248,466Feb 07 07:38 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryJan 08Sale15.1475011,35518,008Jan 08 09:01 PM
Dube Eric MChief Executive OfficerJan 08Sale15.143,75056,77542,500Jan 08 08:49 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryJan 07Sale13.9475010,45518,758Jan 08 09:01 PM
Dube Eric MChief Executive OfficerJan 07Sale13.943,75052,27546,250Jan 08 08:49 PM
ASELAGE STEVEDirectorNov 29Sale13.915,00069,553250,966Nov 29 09:27 PM
Rosenberg Noah L.Chief Medical OfficerJul 31Sale20.071,25025,08813,500Jul 31 09:15 PM
Rosenberg Noah L.Chief Medical OfficerJul 30Sale19.821,25024,77514,750Jul 31 09:15 PM